Stem cells as a therapeutic target for diabetes

Paras Kumar Mishra, Shree Ram Singh, Irving G. Joshua, Suresh C. Tyagi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The rapidly increasing number of diabetes patients across the world poses a great challenge to the current therapeutic approach. The traditional method of exogenous supply of insulin has ephemeral effect and often causes lethal hypoglycemia that demands to develop a novel strategy. Recent investigations on regeneration of insulin producing cells (IPCs) revealed that in addition to primary source i.e., pancreatic beta cells, IPCs can be derived from several alternative sources including embryonic, adult, mesenchymal and hematopoietic stem cells via the process of proliferation, dedifferentiation, neogenesis, nuclear reprogramming and transdifferentiation. There is considerable success in insulin independency of diabetes patient after transplantation of whole pancreas and / or the islet cells. However, the major challenge for regenerative therapy is to obtain a large source of islet / beta cells donor. Recent advances in the directed differentiation of stem cells generated a promising hope for a better and permanent insulin independency for diabetes. In this review we discussed stem cells as a potential future therapeutic target for the treatment of diabetes and associated diseases.

Original languageEnglish (US)
Pages (from-to)461-477
Number of pages17
JournalFrontiers in Bioscience
Volume15
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Medical problems
Stem cells
Stem Cells
Insulin
Islets of Langerhans
Therapeutics
Pancreas Transplantation
Adult Stem Cells
Insulin-Secreting Cells
Embryonic Stem Cells
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Hypoglycemia
Regeneration
Tissue Donors

Keywords

  • Adult stem cells
  • Beta-cells regeneration
  • Diabetes mellitus
  • Human embryonic stem cells
  • Induced pluripotent stem cells
  • Insulin producing cells
  • Mesenchymal stem cells
  • MicroRNAs
  • Nuclear reprogramming
  • Pancreas development
  • Review
  • Stem cell therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Mishra, P. K., Singh, S. R., Joshua, I. G., & Tyagi, S. C. (2010). Stem cells as a therapeutic target for diabetes. Frontiers in Bioscience, 15(2), 461-477. https://doi.org/10.2741/3630

Stem cells as a therapeutic target for diabetes. / Mishra, Paras Kumar; Singh, Shree Ram; Joshua, Irving G.; Tyagi, Suresh C.

In: Frontiers in Bioscience, Vol. 15, No. 2, 01.01.2010, p. 461-477.

Research output: Contribution to journalArticle

Mishra, PK, Singh, SR, Joshua, IG & Tyagi, SC 2010, 'Stem cells as a therapeutic target for diabetes', Frontiers in Bioscience, vol. 15, no. 2, pp. 461-477. https://doi.org/10.2741/3630
Mishra, Paras Kumar ; Singh, Shree Ram ; Joshua, Irving G. ; Tyagi, Suresh C. / Stem cells as a therapeutic target for diabetes. In: Frontiers in Bioscience. 2010 ; Vol. 15, No. 2. pp. 461-477.
@article{d805ab0229704725838e8d4cdee2a26f,
title = "Stem cells as a therapeutic target for diabetes",
abstract = "The rapidly increasing number of diabetes patients across the world poses a great challenge to the current therapeutic approach. The traditional method of exogenous supply of insulin has ephemeral effect and often causes lethal hypoglycemia that demands to develop a novel strategy. Recent investigations on regeneration of insulin producing cells (IPCs) revealed that in addition to primary source i.e., pancreatic beta cells, IPCs can be derived from several alternative sources including embryonic, adult, mesenchymal and hematopoietic stem cells via the process of proliferation, dedifferentiation, neogenesis, nuclear reprogramming and transdifferentiation. There is considerable success in insulin independency of diabetes patient after transplantation of whole pancreas and / or the islet cells. However, the major challenge for regenerative therapy is to obtain a large source of islet / beta cells donor. Recent advances in the directed differentiation of stem cells generated a promising hope for a better and permanent insulin independency for diabetes. In this review we discussed stem cells as a potential future therapeutic target for the treatment of diabetes and associated diseases.",
keywords = "Adult stem cells, Beta-cells regeneration, Diabetes mellitus, Human embryonic stem cells, Induced pluripotent stem cells, Insulin producing cells, Mesenchymal stem cells, MicroRNAs, Nuclear reprogramming, Pancreas development, Review, Stem cell therapy",
author = "Mishra, {Paras Kumar} and Singh, {Shree Ram} and Joshua, {Irving G.} and Tyagi, {Suresh C.}",
year = "2010",
month = "1",
day = "1",
doi = "10.2741/3630",
language = "English (US)",
volume = "15",
pages = "461--477",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Stem cells as a therapeutic target for diabetes

AU - Mishra, Paras Kumar

AU - Singh, Shree Ram

AU - Joshua, Irving G.

AU - Tyagi, Suresh C.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The rapidly increasing number of diabetes patients across the world poses a great challenge to the current therapeutic approach. The traditional method of exogenous supply of insulin has ephemeral effect and often causes lethal hypoglycemia that demands to develop a novel strategy. Recent investigations on regeneration of insulin producing cells (IPCs) revealed that in addition to primary source i.e., pancreatic beta cells, IPCs can be derived from several alternative sources including embryonic, adult, mesenchymal and hematopoietic stem cells via the process of proliferation, dedifferentiation, neogenesis, nuclear reprogramming and transdifferentiation. There is considerable success in insulin independency of diabetes patient after transplantation of whole pancreas and / or the islet cells. However, the major challenge for regenerative therapy is to obtain a large source of islet / beta cells donor. Recent advances in the directed differentiation of stem cells generated a promising hope for a better and permanent insulin independency for diabetes. In this review we discussed stem cells as a potential future therapeutic target for the treatment of diabetes and associated diseases.

AB - The rapidly increasing number of diabetes patients across the world poses a great challenge to the current therapeutic approach. The traditional method of exogenous supply of insulin has ephemeral effect and often causes lethal hypoglycemia that demands to develop a novel strategy. Recent investigations on regeneration of insulin producing cells (IPCs) revealed that in addition to primary source i.e., pancreatic beta cells, IPCs can be derived from several alternative sources including embryonic, adult, mesenchymal and hematopoietic stem cells via the process of proliferation, dedifferentiation, neogenesis, nuclear reprogramming and transdifferentiation. There is considerable success in insulin independency of diabetes patient after transplantation of whole pancreas and / or the islet cells. However, the major challenge for regenerative therapy is to obtain a large source of islet / beta cells donor. Recent advances in the directed differentiation of stem cells generated a promising hope for a better and permanent insulin independency for diabetes. In this review we discussed stem cells as a potential future therapeutic target for the treatment of diabetes and associated diseases.

KW - Adult stem cells

KW - Beta-cells regeneration

KW - Diabetes mellitus

KW - Human embryonic stem cells

KW - Induced pluripotent stem cells

KW - Insulin producing cells

KW - Mesenchymal stem cells

KW - MicroRNAs

KW - Nuclear reprogramming

KW - Pancreas development

KW - Review

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=77951222267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951222267&partnerID=8YFLogxK

U2 - 10.2741/3630

DO - 10.2741/3630

M3 - Article

C2 - 20036830

AN - SCOPUS:77951222267

VL - 15

SP - 461

EP - 477

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 2

ER -